Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
Tóm tắt
Từ khóa
Tài liệu tham khảo
US Food and Drug Administration. Statement of FDA mission. https://www.fda.gov/downloads/aboutfda/reportsmanualsforms/reports/budgetreports/ucm298331.pdf. Accessed May 15, 2017.
US Food and Drug Administration. Science & research: advancing regulatory science. https://www.fda.gov/scienceresearch/specialtopics/regulatoryscience/. Accessed May 15, 2017.
US Food and Drug Administration. Science & research: strategic plan for regulatory science. https://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm267719.htm. Accessed May 15, 2017.
Identifying CDER’s science and research needs report, July 2011. The CDER Science Prioritization and Review Committee (SPaRC). https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM264594.pdf. Accessed May 15, 2017.
Assessing CDER’s Drug Safety-Related Regulatory Science Needs and Identifying Priorities, March 2015. The CDER Safety Research Interest Group (SRIG). https://www.fda.gov/downloads/Drugs/ScienceResearch/UCM438138.pdf. Accessed May 15, 2017.
Fisher AC, Lee SL, Harris DP, et al. Advancing pharmaceutical quality: an overview of science and research in U.S. FDA’s Office of Pharmaceutical Quality. Int J Pharm. 2016;515:390–402.
US Food and Drug Administration. Biomarker qualification program. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/BiomarkerQualificationProgram/default.htm. Accessed May 25, 2017.
Zhang L, Zhang J, Shea K, et al. Autophagy in pancreatic acinar cells in caerulein treated mice: immunolocalization of related proteins and their potential as markers of pancreatitis. Toxicol Pathol. 2014;42:435–457.
Zhang J, Rouse R. Histopathology and pathogenesis of caerulein-, duct ligation-, and arginine-induced acute pancreatitis in Sprague-Dawley rats and C57BL6 mice. Histol Histopathol. 2014;29:1135–1152.
Rouse R, Xu L, Stewart S, et al. Extended exenatide administration exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet. PLoS One. 2014;9:e109477.
Goodwin D, Rosenzweig B, Thompson K, et al. Evaluation of miR-216a and miR-217 as potential biomarkers of acute pancreatic injury in rats and mice. Biomarkers. 2014;25:1–13.
Rouse R, Rosenzweig B, Shea K, et al. MicroRNA biomarkers of pancreatic injury in a canine model. Exp Toxicol Pathol. 2017;69:33–43.
Rouse R, Zhang J, Stewart S, Rosenzweig B, Espandiari P, Sadrieh N. Comparative profile of commercially available urinary biomarkers in preclinical drug-induced kidney injury and recovery in rats. Kidney Int. 2011;79:1186–1197.
Rouse R, Zhang J, Stewart S, Thompson K. Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media. Toxicol Pathol. 2012;41:662–680.
Rouse R, Min M, Francke-Carroll S, et al. Impact of pathologists, blind evaluations, and sampling methods on performance assessment of the kidney injury biomarker, Kim-1. Toxicol Pathol. 2015;43:662–674.
Shea K, Stewart S, Rouse R. Comparison of histopathology, digital image analysis, and stereology for early detection of experimental cisplatin-induced kidney injury in rats. Toxicol Pathol. 2014;42:1004–1015.
Rouse R. Regulatory forum opinion piece: blinding and binning in histopathology methods in the biomarker qualification process. Toxicol Pathol. 2015;43:757–759.
Thompson K, Haskins K, Rosenzweig B, et al. Comparison of the diagnostic accuracy of bis (monoacylglycerol) phosphate and other urinary phospholipids for drug-induced phospholipidosis or tissue injury in the rat. Int J Toxicol. 2012;31:14–24.
Chockalingam AK, Hamed S, Goodwin DG, et al. The effect of oseltamivir on the disease progression of lethal influenza a virus infection: plasma cytokine and miRNA responses in a mouse model. Dis Markers. 2016;2016:9296457.
Mikaelian I, Cameron M, Dalmas DA, et al. Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future. Toxicol Pathol. 2014;42:635–657.
Frazier KS, Engelhardt JA, Fant P, et al. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced vascular injury associated with non-small molecule therapeutics in preclinical development, Part I: Biotherapeutics. Toxicol Pathol. 2015;43:915–934.
Engelhardt JA, Fant P, Guionaud S, et al. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced vascular injury associated with non-small molecule therapeutics in preclinical development, Part 2: Antisense oligonucleotides. Toxicol Pathol. 2015;43:935–944.
Theocharides APA, Rongvaux A, Fritsch K, Flavell RA, Manz MG. Humanized hemato-lymphoid system mice. Haematologica. 2016;101:5–19.
Crawford LB, Tempel R, Streblow DN, et al. Human cytomegalovirus induces cellular and humoral virus-specific immune responses in humanized BLT mice. Sci Rep. 2017;7:937.
Dickie AP, Wilson CE, Schreiter K, et al. The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice. Biochem Pharmacol. 2017;135:139–150.
International Conference on Harmonisation. ICH Topic S7B: the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. 2005.
International Conference on Harmonisation. Guideline for Industry E14: Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005.
Stockbridge N, Morganroth J, Shah RR, Garnett C. Dealing with global safety issues: was the response to QT-liability of non-cardiac drugs well coordinated? Drug Saf. 2013;36:167–182.
Gintant G, Sager P, Stockbridge N. Evolution of strategies to improve preclinical cardiac safety testing. Nat Rev Drug Discov. 2016;15:457–471.
Colatsky T, Fermini B, Gintant G, et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative—update on progress. J Pharmacol Toxicol Methods. 2016;81:15–20.
Fermini B, Hancox JC, Abi-Gerges N, et al. A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm. J Biomol Screen. 2016;21:1–11.
Vicente J, Stockbridge N, Strauss DG. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs. J Electrocardiol. 2016;49:837–842.
Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292–300.
Crumb WJ Jr., Vicente J, Johannesen L, Strauss DG. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel. J Pharmacol Toxicol Methods. 2016;81:251–262.
Li Z, Dutta S, Sheng J, et al. Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-à-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology. Circ Arrhythm Electrophysiol. 2017;10:e004628.
Windley MJ, Abi-Gerges N, Fermini B, Hancox JC, Vandenberg JI, Hill AP. Measuring kinetics and potency of hERG block for CiPA [published online ahead of print February 10, 2017]. J Pharmacol Toxicol Methods. doi: https://doi.org/10.1016/j.vascn.2017.02.017.
Li Z, Dutta S, Sheng J, Tran PN, Wu W, Colatsky T. A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel. J Pharmacol Toxicol Methods. 2016;81:233–239.
O’Hara T, Virag L, Varro A, Rudy Y. Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation. PLoS Comput Biol. 2011;7:e1002061.
Blinova K, Stohlman J, Vicente J, et al. Comprehensive translational assessment of human-induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias. Toxicol Sci. 2017;155:234–247.
Johannesen L, Vicente J, Gray RA, et al. Improving the assessment of heart toxicity for all new drugs through translational regulatory science. Clin Pharmacol Ther. 2014;95:501–508.
Johannesen L, Vicente J, Mason JW, et al. Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther. 2014;96:549–558.
Johannesen L, Vicente J, Mason JW, et al. Late sodium current block for drug-induced long QT syndrome: results from a prospective clinical trial. Clin Pharmacol Ther. 2016;99:214–223.
Vicente J, Johannesen L, Mason JW, et al. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil. J Am Heart Assoc. 2015;4:e001615.
Vicente J, Johannesen L, Hosseini M, et al. Electrocardiographic biomarkers for detection of drug-induced late sodium current block. PLoS One. 2016;11:e0163619.
Johannesen L, Vicente J, Hosseini M, Strauss DG. Automated algorithm for J-Tpeak and Tpeak-Tend assessment of drug-induced proarrhythmia risk. PLoS One. 2016;11:e0166925.
US Food and Drug Administration. March 15, 2017: Pharmaceutical Science and Clinical Pharmacology Advisory Committee meeting announcement. https://www.fda.gov/AdvisoryCommittees/Calendar/ucm535513.htm. Accessed May 15, 2017.
Kruhlak NL, Benz RD, Zhou H, Colatsky TJ. (Q)SAR modeling and safety assessment in regulatory review. Clin Pharmacol Ther. 2012;91:529–534.
Stavitskaya L, Aubrecht J, Kruhlak NL. Chemical structure-based and toxicogenomic models. In: Jacobson-Kram D, Graziano M, eds. Genotoxicity and Carcinogenicity Testing of Pharmaceuticals. New York: Springer;2015:13–34.
International Conference on Harmonisation. M7: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (2014). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_Step_4.pdf. Accessed May 15, 2017.
Amberg A, Beilke L, Bercu J, et al. Principles and procedures for implementation of ICH M7 recommended (Q)SAR analyses. Regul Toxicol Pharmacol. 2016;77:13–24.
Barber C, Amberg A, Custer L, et al. Establishing best practice in the application of expert review of mutagenicity under ICH M7. Regul Toxicol Pharmacol. 2015;73:367–377.
Xu R, Wang Q. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). J Biomed Inform. 2014;47:171–177.
Cheng F, Li W, Wang X, Zhou Y, Wu Z, Tang Y. Adverse drug events: database construction and in silico prediction. J Chem Inf Model. 2013;53:744–752.
Wang Z, Clark NR, Ma’ayan A. Drug-induced adverse events prediction with the LINCS L1000 data. Bioinformatics. 2016;32:2338–2345.
Abernethy DR, Bai JP, Burkhart K, Xie HG, Zhichkin P. Integration of diverse data sources for prediction of adverse drug events. Clin Pharmacol Ther. 2011;90:645–646.
Burkhart KK, Abernethy D, Jackson D. Data mining FAERS to analyze molecular targets of drugs highly associated with Stevens-Johnson syndrome. J Med Toxicol. 2015;11:265–273.
Moore PW, Burkhart KK, Jackson D. Drugs highly associated with infusion reactions reported using two different data-mining methodologies. J Blood Disord Transf. 2014;5:2.
Hur J, Zhao C, Bai J. Systems pharmacological analysis of drugs inducing Stevens Johnson Syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015;28:927–934.
Melas I, Sakellaropoulos T, Iorio F, et al. Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury. Integr Biol. 2015;7:904–920.
Chien H-C, Yang Y-H, Bai J. Trastuzumab-related cardiotoxic effects in Taiwanese women: a nationwide cohort study. JAMA Oncol. 2016;2:1317–1325.
Brouwer KR, Ferguson SS, Lai Y, et al. The importance of in vitro liver models: experts discuss whole-cell systems, transporter function, and the best models for future in vitro testing. Appl In Vitro Toxicol. 2016;2:1–7.
Volpe DA. Transporter assays as useful in vitro tools in drug discovery and development. Expert Opin Drug Discov. 2016;11:91–103.
Hartman N, Zhou H, Mao J, et al. Characterization of the methemoglobin forming metabolites of benzocaine and lidocaine. Xenobiotica. 2017;47:431–438.
Christl LA, Woodcock J, Kozlowski S. Biosimilars: the US regulatory framework. Annu Rev Med. 2017;68:243–254.
Leupke KH, Suda KJ, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy. 2017;37:71–84.
Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016;316:1193–1204.
The Precision Medicine Initiative. https://obamawhitehouse.archives.gov/node/333101. Accessed May 25, 2017.
The Precision Medicine Initiative: What is it? https://syndication.nih.gov/multimedia/pmi/infographics/pmi-infographic.pdf. Accessed May 25, 2017.
Kalydeco FDA Drug Label for NDA 203188 (Action Date 05/01/2017). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203188s019lbl.pdf. Accessed July 8, 2017.
Strauss DG, Vicente J, Johannesen L, et al. Common genetic variants predict drug-induced QT prolongation and torsade de pointes risk: a pilot study. Circulation. 2017;135:1300–1310.